SCHEMBL21775447

SCHEMBL21775447

Cc1nc2cc(-c3ccncc3)nn2c(O)c1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
NPC1 O15118 10/20 0.42
RAB9A P51151 10/20 0.42
ALDH1A1 P00352 6/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
HPGD P15428 4/20 0.42
HTT P42858 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
KDM4E B2RXH2 6/20 0.40
ABCB1 P08183 2/20 0.40
ABCG2 Q9UNQ0 2/20 0.40
DYRK1A Q13627 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP2C19 P33261 1/20 0.40
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21775857 0.88 MAPT (0.57) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775448 0.88 NPC1 (0.55) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21749178 0.85 NPC1 (0.57) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775456 0.85 NPC1 (0.57) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL20502816 0.85 NPC1 (0.46) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775438 0.83 RAB9A (0.41) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775696 0.78 KDM5B (0.42) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL20503090 0.78 CYP11B2 (0.46) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775853 0.76 DPP4 (0.51) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL21775734 0.75 NPC1 (0.36) MAPTNPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2021-03-30 US disclosed
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives RICHTER GEDEON NYRT. (HU) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200061068-A1 Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives GABRA5, P2RX5, P2RY1 MAPT 2067/4885NPC1 1179/4885RAB9A 988/4885
US-10960007-B2 Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, P2RX5, P2RY1 MAPT 2067/4885NPC1 1179/4885RAB9A 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.